11/20/2026 | Press release | Distributed by Public on 11/20/2026 06:34
JLABS Singapore marks three years of growth, collaboration, and scientific progress
Since its launch in October 2023, Johnson & Johnson's JLABS Singapore has been committed to supporting emerging life science and healthcare companies as they translate promising science into potential solutions for patients.
The progress of this JLABS community over the last three years reflects the power of collaboration in accelerating healthcare innovation. Today, it has grown to encompass 59 current and alumni member companies that have collectively raised around US$1.16 billion in funding and several have secured partnerships or deals with Johnson & Johnson.
These milestones represent more than numbers. They reflect the ambition of entrepreneurs pursuing solutions to complex healthcare challenges, the partnerships that help move science forward, and the collective commitment to improving health outcomes for patients around the world.
Building a community to advance healthcare innovation
Singapore continues to strengthen its position as a regional hub for biomedical sciences and healthcare innovation, supported by a strong research ecosystem, world-class talent, and a commitment to translating scientific discoveries into real-world applications. New programs, such as A*STAR's AI Drug Discovery (AIDD) program, represent the next wave of innovation for what may become tomorrow's medicines.
Continued collaboration among startups, investors, research institutions, industry, and government will be important in helping navigate the challenges ahead. We extend our heartfelt thanks to our local government collaborator, the Singapore Economic Development Board, for its continued support and collaboration.
By fostering connections across disciplines and geographies, JLABS Singapore aims to remain a valuable part of the ecosystem supporting the next generation of healthcare innovators. For innovators and entrepreneurs developing potentially transformative healthcare solutions, our community offers new opportunities to connect, collaborate, and move science forward.
Innovation in action
Behind every milestone is a team working to solve a difficult problem. The achievements of JLABS Singapore's member companies demonstrate the breadth of scientific ambition across the community and the different paths innovators take as they advance their technologies. Milestones achieved over the past year include:
Looking ahead: The next chapter
As JLABS Singapore enters its fourth year, the opportunities ahead are significant. Advances across areas such as biotechnology, precision medicine, and AI-enabled research are creating new possibilities for addressing unmet healthcare needs.
"JLABS Singapore has become a vibrant launchpad where bold ideas meet critical support," said Mike Wong, Head of JLABS Singapore. "Our third anniversary is really a celebration of community - of the innovators, investors, partners, and colleagues whose collaboration and resilience have built a supportive ecosystem for early-stage science. Thank you all for making this journey possible. Our next chapter promises to be bright as we continue scaling impact, deepening partnerships, and unlocking new opportunities for health innovation across Singapore and the region."
As the last three years have shown, JLABS Singapore is passionate about our role in bringing entrepreneurial agility together with industry expertise to help innovators navigate the complex journey from scientific discovery to development and commercialization. We look forward to what the next year brings - happy third anniversary, JLABS Singapore!
To learn more about JLABS Singapore and opportunities to join its community, visit JLABS Singapore.
Don't miss a beat & stay connected with JLABS
Subscribe to our Innovation Brief to receive the latest news, highlights, and developments directly in your inbox: https://jnjinnovation.com/subscribe